Multicenter phase I/ II study evaluating maximal tolerated dosage and clinical efficacy of an association of temozolomide with Peg-Intron in patients with metastatic melanoma

Dereure, O.; Khamari, A.; Cupissol, Didier; Delaunay, M.; Bédane, Christophe; Dréno, Brigitte; Guillot, B.

doi:10.1200/jco.2004.22.14_suppl.7548

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, phase I or II trials investigating singleagent temozolomide (n ϭ 9) [8 -16], temozolomide plus IFN-␣ (n ϭ 6) [17][18][19][20][21][22], and temozolomide plus thalidomide (n ϭ 6) [23][24][25][26][27][28] were reviewed. Eleven of the trials were published as full reports [8,10,12,13,15,16,19,20,24,26,28], while 10 were available only in abstract form [9, 11, 14, 17, 18, 21-23, 25, 27].…”

Section: Literature Search Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Temozolomide for the Treatment of Metastatic Melanoma: A Systematic Review

et al. 2007

View full text Add to dashboard Cite

Background. This systematic review examines the role of temozolomide in patients with metastatic melanoma. Outcomes of interest include response rate, progression-free survival, overall survival, quality of life, and adverse effects.Methods. The MEDLINE, EMBASE, and Cochrane Library databases were searched from 1980 through to 2005 using variations on the search terms: melanoma, clinical trial, random, temozolomide, temodal, and temodar. The American Society of Clinical Oncology Annual Meeting proceedings were searched from 1996 to 2005. Relevant articles and abstracts were selected and reviewed by two reviewers, and the reference lists from these sources were searched for additional trials.Results. Two randomized phase III trials and three randomized phase II trials were located. In addition, 21 phase I or II trials investigating single-agent temozolomide, temozolomide plus interferon-␣, and temozolo-

show abstract